|
 |
| home > epc > summer 2003 > life science companies don't plan to fail, but often fail to plan |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
Many companies in the pharmaceutical industry, and especially the biotech sector, are so absorbed in new development or product potential that they could be caught unawares when disaster strikes.
A worldwide survey conducted by Ernst & Young carried out in 2002 found that only 53 per cent of companies have a business continuity plan, and many of these have not been developed or tested (1). Of particular concern is that the survey was published a year after September 11th 2001, an unprecedented event that should have alerted businesses all over the world to their vulnerability to disaster.
Although this survey applies to businesses in general, biotechnology companies, with their laser-like focus on research and development and too little funding, may be even less likely to dedicate the resources required to develop and maintain a comprehensive business continuity plan. However, in order to protect the heavy investment in R&D and years of hard work, it's vital they do all they can to lessen the impact of a disaster on the business.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
